Eli Lilly and Company will supply active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) to increase patient access and improve affordability for high-quality insulin for nearly one million people living with diabetes in Bangladesh by 2030.
Lilly offers its human insulin API at reduced price to IABL to support insulin production in Bangladesh.
This collaboration with IABL, will reduce barriers to access and ensure ongoing production and uninterrupted supply of insulin to help patients to lead healthier lives.
This agreement has a remarkable potential to reach more patients with locally manufactured human insulins using Lilly's API and augment the company's Lilly 30X30 vision to transform communities and make life better for people around the world.
According to the IDF Diabetes Atlas, 13.1 million people are living with diabetes in Bangladesh and it is expected to increase to about 22.3 million by 2045. Through the Lilly 30x30 initiative, Lilly is active in Bangladesh in additional capacities, including nonprofit collaborations to help improve health outcomes for children and adolescents living with chronic, non-communicable diseases (NCDs), and to provide high-quality diabetes care and treatment for children with type 1 diabetes.
